Intraperitoneal administration of interleukin (IL)-1β, IL-6, and IL-2 in mice was shown to stimulate dopamine (DA) utilization in prefrontal cortex, leading to DA deficiency, which is connected with negative symptoms in schizophrenia (Zalcman et al. 1994). The gene discussed is IL1B; the disease is schizophrenia.